Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
Conclusions: Ramucirumab provided a better survival benefit irrespective of BCLC stage and was well tolerated without compromising liver function during treatment.Liver Cancer
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Children | Hepatocellular Carcinoma | Hypertension | Liver | Liver Cancer | Study | Urology & Nephrology